ELDN vs. ZYME, ORIC, NAGE, MENS, SION, REPL, GHRS, XERS, SNDX, and TRVI
Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Zymeworks (ZYME), Oric Pharmaceuticals (ORIC), Niagen Bioscience (NAGE), Jyong Biotech (MENS), Sionna Therapeutics (SION), Replimune Group (REPL), GH Research (GHRS), Xeris Biopharma (XERS), Syndax Pharmaceuticals (SNDX), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry.
Eledon Pharmaceuticals vs. Its Competitors
Eledon Pharmaceuticals (NASDAQ:ELDN) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.
Eledon Pharmaceuticals has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Eledon Pharmaceuticals has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Eledon Pharmaceuticals' return on equity.
Eledon Pharmaceuticals presently has a consensus price target of $9.00, suggesting a potential upside of 143.24%. Zymeworks has a consensus price target of $21.00, suggesting a potential upside of 47.37%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Zymeworks.
56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 12.3% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 1.9% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Eledon Pharmaceuticals and Eledon Pharmaceuticals both had 6 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 0.96 beat Zymeworks' score of 0.77 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.
Eledon Pharmaceuticals has a beta of -0.16, indicating that its share price is 116% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.
Summary
Zymeworks beats Eledon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Eledon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eledon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ELDN) was last updated on 7/19/2025 by MarketBeat.com Staff
